



Financial Tear Sheet

Corporate Profile

Ra Pharma® is a clinical-stage biopharmaceutical company using a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system.

Primary IR Contact

Jennifer Robinson

Phone: 617-674-9873

E-mail:

jrobinson@rapharma.com

Stock Performance

RARX (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$7.95**

Change (%) ▼
0.11 (1.36%)

Volume 392,011

52 Week Low \$7.15

Market Cap \$182,371,073

Rolling EPS -2.47

PE Ratio 0



Shares Outstanding 22,626,684

Data as of December 14, 2017 4:00 p.m. ET

Recent Headlines & Events

December 7, 2017 - 7:12 a.m.

[Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference](#)

December 4, 2017 - 7:00 a.m.

[Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria](#)


November 9, 2017 - 4:22 p.m.

[Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)

Date	Title
December 14, 2017 3:30 p.m. ET	Ra Pharmaceuticals Inc at BMO Capital Markets: Prescriptions for Success Healthcare Conference The Westin Grand Location Central Hotel New York, NY

Analyst Estimates / Ratings

Mean Recommendation: **1.8**



EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Dec 17	-0.66	-0.63	-0.63
QTR	Mar 18	-0.69		
QTR	Jun 18	-0.78		
QTR	Sep 18	-0.82		
FY	Dec 17	-2.37	-2.31	-2.31
FY	Dec 18	-2.34	-2.23	-2.23

SEC Filings

Filing Date	Form
12/08/17	8-K
11/14/17	EFFECT
11/14/17	S-3/A
11/09/17	10-Q

Corporate Governance

Robert Heft
Director

Jason Lettmann
Director

Ed Mathers
Director

Tim Pearson
Director

Rajeev Shah
Director

Peter Tuxen-Bisgaard
Director

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	104	354.14	105.7	23,919,881
Mutual Fund	128	40.11	11.7	2,650,825
Insider *	2	26.11	9.9	2,235,854

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
New Enterprise Associates (NEA)	3,493,636	15.4	0	September 30, 2017
Morgenthaler Ventures	2,745,846	12.1	2,745,846	October 25, 2016
Wellington Management Company, LLP	2,293,041	10.1	187,977	September 30, 2017
Novartis AG	2,252,157	10.0	-208,880	June 19, 2017
Novo Holdings A/S	2,031,562	9.0	0	September 30, 2017
RA Capital Management, LLC	1,351,808	6.0	0	September 30, 2017
Plain (Plain)	1,320,657	5.8	1,320,657	October 25, 2016
Lightstone Ventures, L.P.	1,320,655	5.8	1,320,655	December 31, 2016
VHCP Management, LLC	769,771	3.4	0	September 30, 2017
Millennium Management LLC	631,757	2.8	434,042	September 30, 2017

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)